13F Holdings
中文EN

HKPD Cellyan Biotechnology Co., Ltd IFRS Annual reports only

Wholesale-Drugs, Proprietaries & Druggists' Sundries · Nasdaq · SEC CIK 2007702 · Fiscal year ends 03/31

Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY21.7%
TTM net income YoY-102.0%
TTM EPS YoY-101.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin11.9%
Operating margin-11.2%
Net margin-0.1%
FCF margin2.5%
EBITDA margin-10.9%

Returns

ROE-0.6%
ROA-0.3%
ROIC (approx.)-21.0%
Asset turnover2.25x

Leverage & solvency

Liabilities / assets47.0%
Debt / equity0.38x
Current ratio2.99x
Interest coverage-23.39x

Cash quality & payout

Operating cash flow / net income-21.04x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-03-31FY20242024-03-31FY20232023-03-31
Income statement
Revenue$20.31M$16.69M$12.56M
Cost of revenue$17.90M$13.13M$9.82M
Gross profit$2.42M$3.56M$2.74M
SG&A expense$2.22M$1.89M$1.76M
Operating income-$2.28M-$1.95M-$1.79M
Interest expense$97,667$82,766$23,242
Pretax income$36,112$1.53M$1.02M
Income tax$63,168$196,252$22,574
Net income-$27,056$1.33M$998,196
EBITDA-$2.22M-$1.90M-$1.72M
EPS (basic)-0.000.180.15
EPS (diluted)-0.000.180.15
Weighted avg. shares (diluted)10.21M7.37M6.84M
Banking
Loans, net$1.88M$1.33M—
Balance sheet
Cash & equivalents$748,721$619,575—
Short-term investments$284,546$261,877—
Receivables$4.66M$3.70M—
Inventory$559,982$933,299—
Current assets$8.73M$7.80M—
PP&E, netmay include right-of-use assets (IFRS)$111,245$103,242—
Total assets$9.42M$8.67M—
Current liabilities$2.92M$3.18M—
Short-term debt$371,558$34,704—
Long-term debt$1.50M$1.12M—
Total debt$1.88M$1.15M—
Total liabilities$4.43M$4.41M—
Shareholders' equity$4.99M$4.25M$585,242
Net debt$1.13M$534,405—
Cash flow statement
Operating cash flow$569,214-$394,330$1.73M
Capital expenditure$69,916$52,736$114,643
Free cash flow$499,298-$447,066$1.61M
Investing cash flow-$2.45M-$40,796-$132,095
Financing cash flow$2.00M$537,315-$1.16M
Depreciation & amortization$66,091$58,235$73,986

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.